Allergy & Immunology
The vaccine race against the coronavirus variants, explained
3 Mar, 2021 | 08:52h | UTCThe vaccine race against the coronavirus variants, explained – Vox
How to make ‘immunity passports’ more ethical
3 Mar, 2021 | 08:46h | UTCHow to Make ‘Immunity Passports’ More Ethical – Scientific American
Related: Twelve criteria for the development and use of COVID-19 vaccine passports
Expert consensus on practical aspects in the treatment of chronic urticaria
3 Mar, 2021 | 08:28h | UTC
The predicative clinical features associated with chronic cough that has a single underlying cause
3 Mar, 2021 | 08:14h | UTCNews release: Clinical features for indicating causes of chronic cough – American Academy of Allergy, Asthma & Immunology
Another study shows higher antibody titer responses to a single dose of mRNA vaccine among patients with previous COVID-19 infection
2 Mar, 2021 | 02:13h | UTCRelated: Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection (studies and commentary)
Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge
2 Mar, 2021 | 01:46h | UTC
Commentary on Twitter
“Direct oral challenge safe & effective for de-labelling patients at low risk for true allergy. Important for optimizing patient care and tackling #AMR” https://t.co/S3VL8JXyFJ #JACAMRNews #AMR #AMS @SAPGAbx @lac_cooper @jenny_harbour @raseaton66 @jacquisneddons pic.twitter.com/SwE1yyVr8d
— JAC-AMR (@jac_amr) February 23, 2021
M-A: Treatment with convalescent plasma is not associated with better outcomes in patients with Covid-19
28 Feb, 2021 | 21:51h | UTCEditorial: Emerging Lessons From COVID-19 for the US Clinical Research Enterprise
Commentary on Twitter
Just out: Our meta-analysis in @JAMA_current
"Among patients with COVID-19, treatment with convalescent plasma compared with control was not associated with improved survival or other positive clinical outcomes"https://t.co/tRqpd9v67m
— Lars G. Hemkens (@LGHemkens) February 26, 2021
Short Review: SARS-CoV-2 Vaccines
28 Feb, 2021 | 21:52h | UTCAuthor interview: Coronavirus Vaccines—An Overview
Check out the Table ins this #SARSCoV2 Vaccine Overview – everything you wanted to know about upcoming vaccines – Oxford/AZ, Sputnik, Sinovac, more! https://t.co/TWbgfSKBIP
— JAMA (@JAMA_current) February 26, 2021
Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection
28 Feb, 2021 | 21:49h | UTCStudy 1: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals – The Lancet
Commentary on Twitter (thread – click for more)
New on 1-dose @Pfizer vaccine after prior covid
"We show that individuals with previous #SARSCoV2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation"https://t.co/2G7TRu57OI pic.twitter.com/sIdB0VarqB— Eric Topol (@EricTopol) February 25, 2021
Spain to give just one vaccine dose to under 55-year olds who had COVID-19
28 Feb, 2021 | 21:47h | UTCSpain to give just one vaccine dose to under 55-year olds who had COVID-19 – Reuters
Related: Is One Vaccine Dose Enough After COVID-19 Infection? – NIH Director’s Blog AND France’s health authority recommends single vaccine shot for people who have had COVID-19
Covid-19: In vitro studies show Pfizer-BioNTech and Moderna vaccines produce fewer antibodies against South African variant
19 Feb, 2021 | 03:01h | UTCCommentaries: Expert reaction to two NEJM Correspondence articles on in vitro studies of the Pfizer-BioNTech and Moderna vaccines and different variants/mutations including mutations on the South Africa variant – Science Media Centre AND Lab studies suggest Pfizer, Moderna vaccines can protect against coronavirus variant – CNN AND Pfizer and Moderna vaccines have reduced effectiveness against South African variant, newly published studies show – The Washington Post AND Pfizer, Moderna vaccines less effective against South African COVID variant – MedicalXpress
Commentary on Twitter
New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines pic.twitter.com/2N7eKDllso
— Eric Topol (@EricTopol) February 17, 2021
A food allergy epidemic… or just another case of overdiagnosis?
19 Feb, 2021 | 02:13h | UTCA food allergy epidemic… or just another case of overdiagnosis? – The BMJ Opinion
Original study: Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 – The BMJ
Take whatever COVID vaccine you can get. All of them stop death and hospitalization
15 Feb, 2021 | 01:17h | UTCTake whatever COVID vaccine you can get. All of them stop death and hospitalization – USA Today
“All seven COVID-19 vaccines that have completed large efficacy trials — Pfizer, Moderna, Johnson & Johnson, Novavax, AstraZeneca, Sputnik V and Sinovac — appear to be 100% effective for serious complications. Not one vaccinated person has gotten sick enough to require hospitalization. Not a single vaccinated person has died of COVID-19.”
Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US
15 Feb, 2021 | 01:13h | UTCAuthor interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions – JAMA
Commentary on Twitter
More than 17.5 million doses of Pfizer & Moderna vaccine were administered between Dec 14 – Jan 18, in USA.
Only 66 cases of anaphylaxis were reported & all but 1 case occurred within 11 min of vaccination.
0 deaths.https://t.co/P1YJISkHZE
— Isaac Bogoch (@BogochIsaac) February 12, 2021
Small RCT: Inhaled budesonide reduces the need for hospitalization in COVID-19 patients
11 Feb, 2021 | 02:18h | UTCCommentaries: Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests – University of Oxford AND Expert reaction to preprint on an RCT of inhaled budesonide in the treatment of early COVID-19 – Science Media Centre
Perspective: Leave your antibodies alone
11 Feb, 2021 | 02:12h | UTCLeave Your Antibodies Alone – The Atlantic
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
Covid-19: People who have had infection might only need one dose of mRNA vaccine
3 Feb, 2021 | 01:44h | UTCCovid-19: People who have had infection might only need one dose of mRNA vaccine – The BMJ
Original preprint studies: Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine – medRxiv AND Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 – medRxiv
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma
2 Feb, 2021 | 01:06h | UTCSafety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
CDC Report: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine
25 Jan, 2021 | 01:29h | UTCCommentary: CDC reports rare allergic reactions to Moderna’s Covid-19 vaccine – STAT
Clinical update: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine
22 Jan, 2021 | 08:35h | UTCAuthor interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions
Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma
22 Jan, 2021 | 07:59h | UTCOnset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW Research—#Benralizumab significantly reduced exacerbation risk by 49% vs placebo (RR estimate 0·51, 95% CI 0·39–0·65; p≤0·0001) over the 24-week treatment period in patients with severe eosinophilic #asthma
The ANDHI study from Tim Harrison & co https://t.co/bQwikpQZvc pic.twitter.com/sS9ab0Mo1R
— The Lancet Respiratory Medicine (@LancetRespirMed) January 4, 2021